$1.96 EPS Expected for Taro Pharmaceutical Industries Ltd. (TARO)

October 13, 2018 - By Louis Casey

Analysts expect Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to report $1.96 EPS on November, 6.They anticipate $0.66 EPS change or 50.77 % from last quarter’s $1.3 EPS. TARO’s profit would be $77.27 million giving it 12.20 P/E if the $1.96 EPS is correct. After having $1.71 EPS previously, Taro Pharmaceutical Industries Ltd.’s analysts see 14.62 % EPS growth. The stock decreased 0.28% or $0.27 during the last trading session, reaching $95.65. About 73,133 shares traded or 80.81% up from the average. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 2.92% since October 14, 2017 and is downtrending. It has underperformed by 18.54% the S&P500.

Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company has market cap of $3.77 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It has a 17.03 P/E ratio. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.

More news for Taro Pharmaceutical Industries Ltd. (NYSE:TARO) were recently published by: Businesswire.com, which released: “Taro Terminates Agreement with NovaBiotics” on September 28, 2018. Seekingalpha.com‘s article titled: “Taro Pharma nixes license agreement with NovaBiotics” and published on September 29, 2018 is yet another important article.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.